Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses to the brain may limit stroke damage, early trial hints

NCT ID NCT06064734

Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether low-frequency magnetic stimulation (rTMS) applied to the brain within 48 hours of an acute ischemic stroke could reduce the growth of damaged tissue and lower disability. Sixty adults aged 18–80 with moderate to severe strokes were enrolled. The treatment involved two daily sessions over three days. The goal was to see if this safe, non-invasive approach could improve outcomes without the need for clot-busting drugs or surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low-frequency repetitive transcranial magnetic stimulation (rTMS) device
What this could lead to
If it works, this could point toward a non-drug treatment to limit stroke damage and improve recovery when given soon after a stroke.
What could go wrong
This is a small, early pilot trial with only 60 people, so results may not apply widely. The treatment is also experimental and may not reduce disability or could cause side effects like bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-80 years, gender is not limited; 2. Acute ischemic stroke of anterior circulation was diagnosed clinically 3. mRS 0-1 score before onset; 4. 6 ≤ NIHSS ≤25 at randomization; 5. Within 48 hours of stroke onset; 6. No thrombolysis therapy or thrombectomy is planned; 7. Obtain informed consent signed by the patient himself or by his legal authorized representative. Exclusion Criteria: 1. TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. 2. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; 3. Midline displacement and brain parenchymal mass effect seen in head CT and other images; 4. Head CT or MRI showed bilateral acute cerebral infarction, brainstem infarction, or insular infarction; 5. Evidence of acute intracranial hemorrhage; 6. A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; 7. After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg; 8. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) \< 60 mL/min; 9. Patients during pregnancy or lactation and within 90 days of planned pregnancy; 10. Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; 11. Patients with malignancy or severe systemic disease and expected survival of less than 90 days; 12. Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke, acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke, acute Stroke, ischemic

Contacts and locations

Locations

  • Beijing Tian tan Hospital

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.